Navigation Links
The ECNP consensus statement on bipolar depression
Date:7/8/2008

Bipolar disorder is one of the most complex and challenging mental disorder in the spectrum. Bipolar disorder is typically associated with considerable acute and longterm treatment needs and may be associated in the course of illness with times of tremendous social burden for both the individual and family. It is typically referred to as an episodic, yet lifelong and clinically severe mood disorder. The disorder is called bipolar, because depressive and manic mood episodes alternate in the course of illness. Because the manic part may be sometimes less impairing and disabling, clinicians differentiate the less severe expression with euphoria and/or extreme irritability called hypomania as Bipolar II as opposed to the more dramatic and severe mania (called Bipolar I disorder).

The long-term course of bipolar disorder is usually dominated by depressive rather than (hypo)manic symptoms, and disease onset tends to be earlier than in patients showing only major depression. A major challenge in the treatment of patients with mood disorders is the distinction between bipolar and unipolar depression from early on, since these conditions may require different types of treatment. Unfortunately, all too often patients with bipolar depression remain untreated or improperly treated. Over the last 10-15 years, there has been an increasing awareness and knowledge about bipolar disorder reflecting the explosion on all fronts in the biomedical literature. Everybody struggles to keep up to.

To take account of the accumulating evidence and experience, the European College of Neuropsychopharmacology (ECNP) recently published a consensus statement that provides an expert summary of state-of-the-art knowledge concerning all aspects of bipolar depression, and broader issues of bipolarity. The highlights of this statement will be presented by the renowned British researcher Guy M. Goodwin from the University Department of Psychiatry, Warneford Hospital, Oxford. The apparent differences between unipolar and bipolar depression arise in diagnosis and epidemiology, bipolar depression in children as well as adults, the use of rating scales, and finally treatment studies to optimize pharmacotherapy and clinical outcome.


'/>"/>

Contact: Sonja Mak
s.mak@update.europe.at
43-140-55734
European College of Neuropsychopharmacology
Source:Eurekalert

Related medicine news :

1. Journal of Ultrasound In Medicine features bioeffects consensus report
2. National Quality Forum Endorses Consensus Standards for Quality of Hospital Care
3. CEOs From Multiple Health Industries Announce Consensus Plan to Reform U.S. Health Care
4. Global Consensus on Mercury: Scientists Defend Science Journalists
5. Curbing worlds most fatal diseases: consensus created by health experts offers global prescription
6. Health Information Exchange Consensus Conference Reinforces Key Role of State-Level Entities
7. Polyanalgesic Consensus Panels New Treatment Guidelines Via Intraspinal Infusion for Severe Chronic Pain
8. eHealth Initiative Releases Blueprint Representing Consensus on an Action Plan for Transforming U.S. Healthcare Using Health IT
9. National Quality Forum Issues First Consensus Standards for the Treatment of Substance Use Conditions
10. Blue Cross and Blue Shield Association Statement: Health Care America Now
11. Anthem Blue Cross Statement on Settlement Discussions with the California Department of Managed Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased to announce the ... July 17, 2017, Ms. Vu will join West Dermatology’s large network of medical and ... skin cancer , and more. She graduated from the University of Florida College ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... concussion rates are on the rise, say researchers presenting their work at the ... Ontario, Canada. , “The combination of evaluating the patterns of change in concussion ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia ... that progresses rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and ... and relapse. With such a challenging diagnosis that requires immediate action, patients ...
(Date:7/20/2017)... ... ... For individuals with extended hospital stays or who are residents of nursing homes, ... designed to accommodate patients with a wide range of ailments or special needs, but ... invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features many uses, ...
(Date:7/20/2017)... , ... July 20, 2017 , ... Doctors on Liens, ... addition of Horine Chiropractic , directed by Dr. Russell Horine, DC to their ... completely family run with Dr. Russell Horine serving as the clinic director and his ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... July 11, 2017  Sysmex America, Inc., a ... testing equipment as well as middleware information systems ... to make quality assurance easier and more risk ... well known for the innovation that it delivers ... elevates quality assurance processes to a new level ...
(Date:7/11/2017)... JERUSALEM , July 11, 2017 Oramed ... ), a clinical-stage pharmaceutical company focused on the development ... U.S. Food and Drug Administration (FDA) has agreed to ... successfully completed Phase IIb trial of its oral insulin ... The Phase IIb trial met primary and secondary endpoints ...
(Date:7/10/2017)... , July 10, 2017 The Institute for ... methods, is the recipient of a VITROCELL® inhalation exposure ... International Science Consortium. The device, which is designed to ... expose human lung cells to airborne test materials in ... use the VITROCELL® system for testing combustible tobacco products, ...
Breaking Medicine Technology: